
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Approvals· May 26, 2026 · 8 min read
By Ran Chen#FDA Approval#Novel Drug Approvals#GLP-1

Approvals· May 25, 2026 · 8 min read
FDA complete response letter guide: CRLs, resubmission, and transparency

Manufacturing· May 22, 2026 · 13 min read
API supplier change control: DMF letter-of-authorization and notification traps

Manufacturing· May 22, 2026 · 10 min read
CDMO quality agreement red flags that become FDA inspection findings
By Ran Chen#Manufacturing Capacity#CMC#FDA Approval

Manufacturing· May 22, 2026 · 14 min read
CMC-only complete response letters: how commercial teams should read the risk
By Ran Chen#Manufacturing Capacity#CMC#FDA Approval

Manufacturing· May 22, 2026 · 12 min read
Global CMC change classification mismatch between FDA, EMA, and non-ICH markets
By Ran Chen#CMC#Post-Approval Changes#ICH

Manufacturing· May 22, 2026 · 14 min read
ICH Q12 established conditions in regulatory submissions
By Ran Chen#CMC#ICH#Regulatory

Policy· May 22, 2026 · 11 min read
Labeling supplement timing after a new indication approval and why launch teams miss it

Manufacturing· May 22, 2026 · 10 min read
PAI readiness for a launch-critical facility when approval timing is tight
Policy· May 22, 2026 · 10 min read